



08-26-04

FEW

PATENTS
671308-2001.1

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Minoru FUJIMORI et al
Serial No. : 10/782,899
For : ANAEROBIC BACTERIUM AS A DRUG FOR CANCER
GENE THERAPY
Filing Date : February 23, 2004
Examiner : Brian A. Whiteman
Group Art Unit : 1635

EXPRESS MAIL

Mailing Label Number: EV 467848182 US

Date of Deposit: August 23, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles Jackson
(Typed or printed name of person mailing paper or fee)

Charles Jackson
(Signature of person mailing paper or fee)

745 Fifth Avenue
New York, NY 10151

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97(B)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully directed to the documents listed on the enclosed PTO-1449 (in duplicate). Since these documents were either cited to or cited by the Examiner in the predecessor application (U.S. Serial No. 09/816,391 filed March 26, 2001) and are of record in the predecessor application, a copy of each of these documents should be in the predecessor

application file. Accordingly, no additional copies are being forwarded with this Information Disclosure Statement; but will gladly be supplied upon request.


This Information Disclosure Statement is not a representation that the documents cited herein are considered most pertinent, or that a search has been undertaken, or that any of the cited documents are indeed prior art. The Examiner is invited to undertake an independent search.

Applicants respectfully request that the Examiner consider and make of record the documents cited herein and that a copy of the Form PTO-1449, initialed by the Examiner be returned to the undersigned. Entry of this Information Disclosure Statement and an early examination on the merits are respectfully solicited.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits, it is believed that no fee is required for entry of this paper. However, the Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Deborah L. Lu
Thomas J. Kowalski
Reg. No. 52,147
Deborah L. Lu, Ph.D.
Reg. No. 50,940
Tel.: (212) 588-0800

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 671308-2001		SERIAL NO. 10/782,899	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) 				APPLICANT Minoru FUJIMORI et al			
				FILING DATE February 23, 2004		GROUP 1635	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,486,407	02-1983	Taguchi	424	85	
	AB	2002-0006432 A1	07-2001	Collins et al.	424	439	
	AC	6,416,754	7/2002	Brown et al.			
	AD	2002/0182229	12/2002	Brown et al.			
	AE	2003/0103952	6/2003	Brown et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AF	WO 96/11277	10/1995	WIPO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AG	M J Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment", Gene Therapy, Vol. 4, 1997, pp. 791-796.					
	AH	N. Minton et al., "Chemotherapeutic tumor targeting using clostridial spores", FEMS Microbiology Reviews, Vol. 17, 1995, pp. 357-364					
	AI	Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, October 4-6, 2000, Yokohama, Vo. 91 Supplement, No. 1880 as well as its English translation and Verification of translation.					
	AJ	Yazawa et al., Cancer Gene Therapy, Vol. 17, pp. 269-274 published on March 27, 2000 as well as a copy of the certificate. K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF α induction retain tumor-targeting <i>in vivo</i> ", Nature Biotechnology, Vol. 17, January 1999, pp. 37-41.					
	AK	K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF α induction retain tumor-targeting <i>in vivo</i> ", Nature Biotechnology, Vol. 17, January 1999, pp. 37-41					
	AL	G. Dachs et al., "Targeting gene expression to hypoxic tumor cells", Nature Medicine, Vol. 3, No. 5, May 1997, pp. 515-520.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Based on Form PTO-1449 (3/90)		ATTY. DOCKET NO. 671308-2001	SERIAL NO. 10/782,899
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Minoru FUJIMORI et al	
		FILING DATE February 23, 2004	GROUP 1635
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AM	H. Matsumura et al., "Construction of <i>Escherichia coli</i> - <i>Bifidobacterium longum</i> shuttle vector transforming <i>B. longum</i> 105-A and 108-A", Biosci. Biotech. Biochem., Vol. 61, No. 7, 1997, pp. 1211-1212.	
	AN	A. Argnani et al., "A convenient and reproducible method to genetically transform bacteria of the genus <i>Bifidobacterium</i> ", Microbiology, Vol. 142, 1996, pp. 109-114.	
	AO	N. Kimura et al., "Selective localization and growth of <i>Bifidobacterium bifidum</i> in mouse tumors following intravenous administration", Cancer Research, Vol. 40, June 1980, pp. 2061-2068.	
	AP	M. Fox et al., "Anaerobic bacteria as a delivery system for cancer gene therapy: <i>in vitro</i> activation of 5-fluorocytosine by genetically engineered clostridia", Gene Therapy, Vol. 3, 1996, pp. 173-178.	
	AQ	C. Tacket et al., "Comparison of the Safety and Immunogenicity of Δ aroC Δ aroD and Δ cya Δ crp <i>Salmonella typhi</i> Strains in Adult Volunteers", Infection and Immunity, Vol. 60, No. 2, pp. 536-541, February 1992.	
	AR	H. Yasui et al., "Enhancement of Immune Response in Peyer's Patch Cells Cultured with <i>Bifidobacterium breve</i> ", Journal of Dairy Science, Vol. 74, pp. 1187-1195, 1991.	
	AS	D. Salzman et al., "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent", Cancer Biotherapy and Radiopharmaceuticals, Vol. 11, No. 2, pp. 145-153, 1996.	
	AT	J. Saavedra et al., "Feeding of <i>Bifidobacterium bifidum</i> and <i>Streptococcus thermophilus</i> to Infants in Hospital for Prevention of Diarrhoea and Shedding of Rotavirus", The Lancet, Vol. 344, pp. 1046-1049, October 15, 1994	
	AU	B. Reddy et al., "Inhibitory Effect of <i>Bifidobacterium longum</i> on Colon, Mannary, and Liver Carcinogenesis Induced by 2-Amino-3-methylimidazo[4,5-f]quinoline, a Food Mutagen", Cancer Research, Vol. 53, pp. 3914-3918, September 1, 1993.	
	AV	D. Hone et al., "Evaluation in Volunteers of a Canadidate Live Oral Attenuated <i>Salmonella typhi</i> Vector Vaccine", Journal of Clinical Investigation, Vol. 90, pp. 412-420, 1992.	
	AW	M. Babincova et al., Life and medical Sciences Online, (2000), 1, pp. 1-4.	
	AX	IM Verma et al., Nature, "Gene therapy-promises, problems and prospects," Sep. 1997, Vol. 389, pp. 239-242.	
	AY	WF Anderson, Nature, "Human gene therapy", Apr. 1998, Vol. 392, pp. 25-30.	
	AZ	K Yazawa et al., Breast Cancer Research and Treatment, "Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors," 2001, 66, pp. 156-170.	
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			